Literature DB >> 11832680

Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.

Marina Pierdominici1, Antonello Giovannetti, Fabrizio Ensoli, Francesca Mazzetta, Marco Marziali, Maria Rita De Cristofaro, Donatella Santini-Muratori, Wilma Leti, Fernando Aiuti.   

Abstract

The effect of highly active antiretroviral therapy (HAART) on the expression of CCR5 and CXCR4 HIV coreceptors and the production of the beta-chemokines regulated upon activation, normal T-cell expressed and secreted (RANTES), macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta has been investigated in 30 HIV-1-infected individuals during 12-36 months of therapy. CCR5 expression was increased in both CD4 + and CD8 + subsets, whereas CXCR4 expression was upregulated only in CD4 + cells. CCR5 levels normalized during 36 months of therapy and positively correlated with the levels of memory, CD95 +, and HLA-DR + T cells. In contrast, the frequency of CXCR4-expressing cells was not significantly modified by HAART, although a downregulation was observed early after starting treatment. CXCR4 levels were significantly associated with the frequencies of naive T cells and negatively correlated with plasma viral load, CD95, and HLA-DR expression. An increased production of both spontaneous and lectin-induced RANTES, MIP-1alpha, and MIP-1beta was found at baseline in HIV-infected individuals. The spontaneous beta-chemokines production was not modified by 12 months of HAART, although a significant reduction was seen during the first months of therapy. A transient decrease of lectin-stimulated RANTES production was also observed, whereas the reduction of lectin-induced MIP-1alpha persisted for up to 12 months of therapy. In contrast, MIP-1beta secreted by phytohemagglutinin antigen-stimulated peripheral blood mononuclear cells progressively increased during HAART. In conclusion, our data indicate a normalization of CCR5 but not CXCR4 expression during suppressive therapy and changes in beta-chemokine production that may play a part in dictating the efficiency of viral infection and consequently the disease course.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832680     DOI: 10.1097/00042560-200202010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Highly active antiretroviral therapy and beta-chemokines.

Authors:  B Brichacek; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India.

Authors:  Ujjwal Neogi; Sreenivasa B Prarthana; George D'Souza; Ayesha Decosta; Vijesh S Kuttiatt; Udaykumar Ranga; Anita Shet
Journal:  AIDS Res Ther       Date:  2010-07-21       Impact factor: 2.250

3.  CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Authors:  Timothy J Henrich; Emily Hanhauser; Linda J Harrison; Christine D Palmer; Marisol Romero-Tejeda; Stephanie Jost; Ronald J Bosch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2015-10-28       Impact factor: 5.226

4.  People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells.

Authors:  Louise E van Eekeren; Vasiliki Matzaraki; Zhenhua Zhang; Lisa van de Wijer; Marc J T Blaauw; Marien I de Jonge; Linos Vandekerckhove; Wim Trypsteen; Leo A B Joosten; Mihai G Netea; Quirijn de Mast; Hans J P M Koenen; Yang Li; André J A M van der Ven
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

5.  Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.

Authors:  Andrew Owen; Becky Chandler; Patrick G Bray; Stephen A Ward; C Anthony Hart; David J Back; Saye H Khoo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.

Authors:  Anjana Yadav; Michael R Betts; Ronald G Collman
Journal:  J Neurovirol       Date:  2016-03-28       Impact factor: 2.643

7.  High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment.

Authors:  Elizabeth R Johnston; Lynn S Zijenah; Solomon Mutetwa; Rami Kantor; Chonticha Kittinunvorakoon; David A Katzenstein
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.

Authors:  Hinta Meijerink; Agnes R Indrati; Reinout van Crevel; Irma Joosten; Hans Koenen; Andre J A M van der Ven
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.